Loading…
5 companies · GEL, thousands · columns ordered by revenue
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Line item | JMP | Medinservi Company | Medeksporti | Es Ka Impex | Net Pharma Sakartvelo |
|---|---|---|---|---|---|
| Total Revenue | 9,032 | 8,753 | 8,314 | 8,048 | — |
| Total COGS | -7,137 | -4,992 | -5,026 | -4,087 | — |
| Gross Profit | 1,895 | 3,761 | 3,289 | 3,961 | — |
| Gross Margin | 21.0% | 43.0% | 39.6% | 49.2% | — |
| Total Operating Expenses | -15 | -2,513 | -225 | -2,536 | — |
| EBITDA | 1,880 | 1,538 | 3,063 | 1,425 | — |
| EBITDA Margin | 20.8% | 17.6% | 36.8% | 17.7% | — |
| Total D&A | -45 | -362 | -11 | 0 | — |
| EBIT / Operating Income | 1,835 | 1,177 | 3,053 | 1,425 | — |
| Total Other Income | 1,272 | -494 | 19 | -18 | — |
| Profit Before Tax | 3,107 | 683 | 3,072 | 1,391 | — |
| Total Income Tax | -160 | 0 | 0 | -261 | — |
| Net Profit / (Loss) | 2,083 | 622 | 3,072 | 1,130 | — |
| Net Margin | 23.1% | 7.1% | 36.9% | 14.0% | — |
| Other Operating Income | — | 291 | — | — | — |
| Total Interest Income | — | — | — | 5 | — |
| Total Interest Expense | — | — | — | -21 | — |
Not every picked company reports every selected year — FY2024: no filing for Net Pharma Sakartvelo. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Medeksporti | Pharma | 36.8% | 87th pct | 110 |
| JMP | Pharma | 20.8% | 62nd pct | 110 |
| Es Ka Impex | Pharma | 17.7% | 55th pct | 110 |
| Medinservi Company | Pharma | 17.6% | 53rd pct | 110 |
| Net Pharma Sakartvelo | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.